Analysts say these ASX 200 shares could rise 30% to 40%

If you are looking to bolster your portfolio with some growing ASX 200 shares, then it could be worth taking a look at the two in this article.

That’s because analysts rate them as top buys and are expecting them to generate big returns for investors over the next 12 months.

Here’s what they are recommending to clients:

ResMed Inc. (ASX: RMD)

The first ASX 200 growth share that could be a strong buy is ResMed. It is a world leader in sleep apnoea treatment and respiratory care, serving a patient base that continues to grow as awareness improves and diagnosis rates increase.

More than one billion people globally are estimated to suffer from sleep apnoea, yet the vast majority remain undiagnosed. As testing becomes easier and healthcare systems catch up, that number represents a massive multi-decade growth runway for ResMed.

The company’s device ecosystem, software solutions, and cloud-connected monitoring tools create high switching costs and drive recurring revenue. This has seen ResMed continue to expand its margins, improve operating leverage, and grow its earnings at a solid rate.

With ageing populations, rising obesity rates, and increased global focus on respiratory care, ResMed is well placed to remain a dominant global medical technology company for many decades.

The team at Macquarie is bullish on this name. It recently put an outperform rating and $49.20 price target on its shares. This implies potential upside of 30% for investors over the next 12 months.

Web Travel Group Ltd (ASX: WEB)

Web Travel could be another ASX 200 growth share to buy. Following the spin-off of its online travel business into a separate listing, the company’s focus is now on WebBeds.

It is a platform that connects hotels and other travel service suppliers to a distribution network of travel buyers all over the world.

Travel demand continues to normalise globally, and wholesale accommodation platforms are benefiting from strong cross-border migration, rising mobility, and the shift toward digital booking ecosystems.

WebBeds’ business model offers high scalability and attractive operating leverage. And after a mixed few years, the company’s simplified structure, improving market conditions, and clearer strategic direction have positioned it well for a meaningful rebound.

Many analysts believe earnings could accelerate from here. One of those is Ord Minnett, which recently put a buy rating and $7.00 price target on the company’s shares. Based on its current share price, this implies potential upside of over 40% for investors from current levels.

The post Analysts say these ASX 200 shares could rise 30% to 40% appeared first on The Motley Fool Australia.

More reading

• Top Australian stocks to buy right now with $2,000
• The smart way to make a $25,000 passive income from ASX shares
• Top ASX shares to buy now for long-term growth
• ASX retail shares: 2 to buy and 1 to sell amid rising inflation
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in ResMed and Web Travel Group Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.